Inclusion Criteria:

        For inclusion in the study subjects must fulfill all of the following criteria:

          1. Written informed consent obtained from the patient/legal representative prior to
             performing any protocol-related procedures, including screening evaluation.

          2. Newly diagnosed, untreated, biopsy proven non-small cell lung cancer.

          3. Medically inoperable or patient refusal to surgery as defined by any single of the
             following criteria: a. Determined unfit for surgery by thoracic surgeon or radiation
             oncologist as documented in the medical record b. Pulmonary function test (PFTS)
             showing Forced Expiratory Volume in the first second (FEV1) ≤ 1.2 L or diffusing Lung
             Capacity (DLC) <60%, c. Poor exercise tolerance or failed pre-operative cardiac
             work-up, d. Patient refusal to undergo definitive surgery as documented in clinical
             note by a surgeon, pulmonologist, medical oncologist, or radiation oncologist.

          4. Clinically stage I disease by American Joint Committee on Cancer (AJCC) 7th edition.
             (N0, M0, T stages T1-T2a) or patients with stage T2bN0M0 (clinical stage IIA) disease
             who are medically unfit for standard of care chemotherapy as documented by a medical
             oncologist or radiation oncologist, or who refuse standard of care chemotherapy as
             documented by a medical oncologist or radiation oncologist.

          5. Age > 18 years at time of study entry.

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.

          7. Adequate normal organ and marrow function as defined below:

               -  Haemoglobin ≥ 9.0 g/dL.

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (> 1500 per mm3).

               -  Platelet count ≥ 100 x 109/L (>100,000 per mm3).

               -  Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). <<This will
                  not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent
                  hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis
                  or hepatic pathology), who will be allowed only in consultation with their
                  physician.>>

               -  aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT)/
                  alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) ≤ 2.5 x
                  institutional upper limit of normal unless liver metastases are present, in which
                  case it must be ≤ 5x ULN.

               -  Serum creatinine creatinine clearance (CL) >40 mL/min by the Cockcroft-Gault
                  formula (Cockcroft and

             Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:

             Males:

             Creatinine CL (mL/min)

             = Weight (kg) x (140 - Age) . 72 x serum creatinine (mg/dL)

             Females:

             Creatinine CL (mL/min)

             = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)

          8. Female subjects must either be of non-reproductive potential (i.e. post-menopausal by
             history: ≥60 years old and no menses for ≥1 year without an alternative medical cause;
             OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of
             bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

          9. Subject is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

        Exclusion Criteria:

          1. ECOG Performance status >1.

          2. Patients with metastatic or node positive NSCLC.

          3. Patients with prior radiation therapy to the same bronchopulmonary segment.

          4. History of automimmune disease including myasthenia gravis, myositis, autoimmune
             hepatitis, systemic lupus erythematous, rheumatoid arthritis, inflammatory bowel
             disease (e.g., Crohn's disease, ulcerative colitis), vascular thrombosis associated
             with antiphospholipid syndrome, Wegner's granulomatosis, Sjogren's syndrome,
             Guillain-Barre syndrome, multiple sclerosis, or glomerulonephritis.

             a. However, patients with type 1 diabetes mellitus, vitiligo, alopecia, hypothyroidism
             requiring hormone replacement, Graves disease, or skin disorders not requiring
             systemic treatment are permitted to enroll.

          5. Patients with history of idiopathic pulmonary fibrosis, idiopathic pneumonitis, drug
             induced pneumonitis, or evidence of active pneumonitis on screening chest CT scan.

          6. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site).

          7. Participation in another clinical study with an investigational product during the
             last 6 months.

          8. Any previous treatment with a Programmed Death-1 (PD1) or Programmed Death-Ligand
             1(PD-L1) inhibitor, including durvalumab, and therapeutic anticancer vaccine.

          9. History of another primary malignancy except for:

               1. Malignancy treated with curative intent and with no known active disease ≥5 years
                  before the first dose of study drug and of low potential risk for recurrence.

               2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease.

               3. Adequately treated carcinoma in situ without evidence of disease e.g., cervical
                  cancer in situ.

         10. Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3
             electrocardiograms (ECGs) using Frediricia's Correction.

         11. Current or prior use of immunosuppressive medication within 28 days before the first
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid.

         12. Any unresolved ≥ Grade 2 pulmonary toxicity from previous anti-cancer therapy.

         13. Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous
             immunotherapy agent, or any unresolved irAE >Grade 1.

         14. History of primary immunodeficiency.

         15. History of allogeneic organ transplant.

         16. History of hypersensitivity to durvalumab or any excipient.

         17. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active
             bleeding diatheses including any subject known to have evidence of acute or chronic
             hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric
             illness/social situations that would limit compliance with study requirements or
             compromise the ability of the subject to give written informed consent.

         18. Known history of previous clinical diagnosis of tuberculosis.

         19. History of leptomeningeal carcinomatosis.

         20. Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving durvalumab.

         21. Female subjects who are pregnant, breast-feeding or male or female patients of
             reproductive potential who are not employing an effective method of birth control.

         22. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of study treatment or interpretation of patient safety or study results.

         23. Subjects with uncontrolled seizures. -